LJH685 is primarily utilized in the field of pharmaceutical research and development, particularly in the study of targeted cancer therapies. It functions as a selective PI3Kδ inhibitor, designed to interact with specific molecular pathways involved in the growth and proliferation of cancer cells, especially in hematological malignancies. Researchers employ LJH685 to investigate its potential in blocking these pathways, thereby inhibiting tumor progression and enhancing the efficacy of existing treatments. Its application extends to preclinical studies, where it is tested for its ability to improve therapeutic outcomes in various cancer models. Additionally, LJH685 is used in combination therapies to assess synergistic effects with other anticancer agents, aiming to develop more effective and personalized treatment strategies.